Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909140 · ClinicalTrials.gov registry record · NA
Optimal Method for Mydriasis in Cataract Surgery
A NA study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT02909140: Clinical Trial NA study, sponsored by Johns Hopkins University.
NCT02909140 is a NA study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02909140, a NA study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Obtaining appropriate mydriasis prior to cataract surgery is an important variable in successful surgery. The current practice includes using topical anticholinergic and sympathomimetic agents in the preoperative area prior to cataract surgery, but the pupils are sometimes insufficiently dilated and can often need additional mydriasis with intracameral agents during cataract surgery. Pre-operative topical mydriatic drops take time to take effect, are mildly uncomfortable for the patient, and have a cost to the healthcare system. If intracameral mydriasis alone can achieve adequate pupil dilation, perhaps topical mydriatics would not be needed. The purpose of this study is to evaluate whether topical versus intracameral versus topical + intracameral mydriasis is the optimal way to dilate pupils during routine cataract surgery. The results of this study have implications for improving the efficiency and reducing time prior to cataract surgery. In addition, it has significant potential to reduce the cost associated with cataract surgery if preoperative drops can be eliminated.
Interventions
- DRUG Topical phenylephrine 2.5%
- DRUG Topical cyclopentolate 1%
- DRUG Intracameral Lidocaine 1%
- DRUG Intracameral 0.2- 0.3ml of epinephrine 1:10,000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-08-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02909140
The ClinicalTrials.gov registry entry for NCT02909140 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Topical phenylephrine 2.5% is the first listed.
NCT02909140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02909140 about?
NCT02909140 is a clinical study titled "Optimal Method for Mydriasis in Cataract Surgery". Obtaining appropriate mydriasis prior to cataract surgery is an important variable in successful surgery. The current practice includes using topical anticholinergic and sympathomimetic agents in the preoperative area prior to cataract surgery, but the pupils are sometimes insufficiently dilated and...
What is the current status of trial NCT02909140?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2016-09. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT02909140?
The interventions under investigation include: Topical phenylephrine 2.5% (DRUG), Topical cyclopentolate 1% (DRUG), Intracameral Lidocaine 1% (DRUG), Intracameral 0.2- 0.3ml of epinephrine 1:10,000 (DRUG).
Who is sponsoring clinical trial NCT02909140?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.